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Thyroid malignant neoplasm develops from follicular or parafollicular thyroid cells. A higher proportion of anaplastic
thyroid cancer has an adverse prognosis. New drugs are being used in clinical treatment. However, for advanced
thyroid malignant neoplasm such as anaplastic thyroid carcinoma, the major impediment to successful control of
the disease is the absence of effective therapies. Oncolytic virotherapy has significantly progressed as therapeutics
in recent years. The advance is that oncolytic viruses can be designed with biological specificity to infect, replicate
and lyse tumor cells. Significant advances in virotherapy have being achieved to improve the accessibility, safety
and efficacy of the treatment. Therefore, it is necessary to summarize and bring together the main areas covered by
these investigations for the virotherapy of thyroid malignant neoplasm. We provide an overview of the progress in
virotherapy research and clinical trials, which employ virotherapy for thyroid malignant neoplasm as well as the
future prospect for virotherapy of thyroid malignant neoplasms.
Keywords: Oncolytic virotherapy, Thyroid malignant neoplasm, Thyroid cell biomarkerBackground
Thyroid malignant neoplasm (TMN) occurs in the
follicular or parafollicular thyroid cells. Thyroid, a
butterfly-shaped gland located at the base of neck, pro-
duces hormones that regulate heart rate, blood pres-
sure, body temperature and weight. Thyroid malignant
neoplasm is the most common endocrine malignancy,
accounting for 1.9% of all new malignant tumors diag-
nosed annually in the United States [1]. TMN can be
classified according to their histopathological charac-
teristics. Papillary (PTC), follicular (FTC), and anaplastic
thyroid carcinomas (ATC) arise from endodermal-derived
follicular cells, which represent the most abundant cellular
population of the thyroid gland. PTC comprises 80% to
85% of all thyroid neoplasms, which is frequent in young
females with excellent prognosis. FTC is accounting for
approximately 10% to 15% of cases. PTC and FTC will
lie in the low-risk group, have a low recurrence rate
(<5%) and excellent survival rate (>98%) [2]. The least
common histotype is ATC (1–2%), which has a rapid
progression and a very poor prognosis with a mean* Correspondence: mingxuguan@gmail.com
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unless otherwise stated.survival time of 2–6 months. Surgery, radiotherapy and
chemotherapy do not improve survival [3]. Medullary
thyroid carcinoma (MTC), about 3% of all thyroid cancer
cases, originates from parafollicular C cells, which produce
the hormone calcitonin. Currently, the most effective
management of aggressive thyroid malignant neoplasm
is surgical removal of the thyroid, followed by radio-
active iodine ablation and TSH-suppression therapy.
However, more effective therapies are urgently needed to
minimize dismal outcomes for the thyroid malignant neo-
plasm [4]. Oncolytic virotherapy is a promising anti-cancer
strategy, because it can provide a local regional control,
or eradication of tumors without cross-interference
with standard therapies [5]. Oncolytic viruses can be
divided into wild type viruses that are naturally oncolytic
such as reovirus, measles virus, Newcastle disease virus
(NDV), myxoma virus (MYXV), and vesicular stomatitis
virus (VSV) and those that require genetic modification for
selective oncolysis. Genetic modification for selective onco-
lysis involves either the insertion or deletion of genes [6-9].
In this review, we have recapitulated the important
findings that were obtained in preclinical and clinical trials
for the treatment of TMN, as well as the future goals,
with a particular focus on the strategies in the design of
virotherapy.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The viruses used for TMN mainly include three DNA
viruses (Adenovirus, Herpesvirus and Vaccinia virus)
and five RNA viruses (Reovirus, Newcastle disease virus,
Vesicular stomatitis virus, Measles virus and Retrovirus).
These viruses have been studied as potential therapeutics
for monotherapy, or combination therapy in conjunction
with chemotherapy and/or radiation therapy in pre-clinical
or clinical trials (Table 1). We discuss these viruses in the
order of the clinical study progress for TMN treatment.
Adenovirus - preclinical and clinical studies
Adenoviruses (Adv) are medium-sized (90–100 nm), none-
nveloped viruses with an icosahedral nucleocapsid contain-
ing a double stranded DNA (dsDNA) genome between 26
and 48 Kb. This allows the virus to encode for 22 to 40
genes [10]. The two currently established receptors are
CD46 for the group B human adenovirus serotypes and
the coxsackievirus adenovirus receptor (CAR) for all other
serotypes. A co-receptor is called αv integrin that results in
endocytosis of the virus particle via clathrin-coated pits
[11]. In this process, a series of viral proteins co-operate to
promote efficient replication of the virus and its release.
These major viral proteins include E1A, E1B-55kD, E1B-
19kD, E3-11.6 kD and other associated proteins [12].
Human adenovirus have 57 distinct adenoviral sero-
types have been found to cause a wide range of illnesses,
from mild respiratory infections in young children to
life-threatening multi-organ disease in people with a
weakened immune system. Nearly all adults have anti-
bodies to endemic serotypes 1, 2, 5, or 6 [13].
Various Adenovirus strains have been explored exten-
sively as a viral vector for gene therapy and also as an
oncolytic virus. A common strategy in adenovirus workTable 1 Oncolytic viruses in TMN clinical trials
Virus Genome Genetic alterations De
Adenovirus dsDNA P53 (rAD-p53) IT
P53 (ONYX-015) IT
Fas-c (VB-111) IV
Reovirus dsRNA Natural strain (RT3D) IT
IT/
Herpes simplex virus dsDNA N/A
Vaccina virus dsDNA N/A
New castle disease virus ssRNA N/A
Vesicular virus ssRNA N/A




IV, Intra-venous injection.is to express an enzyme inhibitor, a suicide gene such as
express herpes simplex virus (HSV) thymidine kinase
(tk) and then administer ganciclovir (GCV), or express
p53, interleukin-2 (IL-2) and interleukin-12 (IL-12), or
human sodium iodide symporter (NIS) or pigment epithe-
liumderived, factor (PEDF) as a potent inhibitor of tumor
angiogenesis [14] and then used in combination therapy.
Combination approaches have been explored as means to
promote adenovirus replication and killing at tumor sites.
Shen et al. [15] constructed an oncolytic adenovirus
with a Survivin targeted small hairpin RNA and a re-
porter gene (ZD55-Sur-EGFP). The virus can replicate
specifically in cancer cells, reduce effectively both the
expression of mRNA and protein expression of Survivin
(P <0.0001), induce cancer cell apoptosis and inhibit
human colon adenocacinoma SW480 cell line growth
both in vitro and in vivo [15]. Minemura et al. [16] char-
acterized two adenovirus-derived vectors, which were
combined with GCV to inhibit the growth of MTC cells.
These two adenoviral-based vector systems were termed
AdCMVtk and AdDCTtk. The latter contains human
CALC-I minigene under the control of the CALC-I pro-
moter, whereas the former carries the HSVtk gene driven
by the human cytomegalovirus promoter. All cell lines
transduced with AdCMVtk were rendered sensitive to
GCV. Cell killing was also observed in HeLa, HepG2, rat
MTC and TT (human MTC) cells by the combination of
GCV and AdDCTtk vector [16]. Zhang et al. [17] evalu-
ated cell-specific killing activity of replication defective
adenovirus transducing TK gene under the control of the
rat thyroglobulin (rTg) promoter (AdrTgtk) and then to
transduce various cell lines. When FRTL-5 cells were
infected with AdrTgtk followed by GCV treatment, more
than 90% were killed [17]. Moreover, the enhancedlivery Combination Phase References
Radioactive iodine/ Surgery IV 24
Cisplatin/5-fluorouracil Marketed 27
Anti-angiogenic agent II 29
Low-dose radiation/ II 35
IV
Gemcitabine/Carboplatin/
Paclitaxel/Docetaxel III 37. 38
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and combined HSV-tk/GCV, IL-12 [19] and p53 [20] have
also been evaluated. The tumor suppressor p53 is a tran-
scription factor that regulates cell cycling, DNA repair and
apoptosis. However, p53 mutations are not frequent in
thyroid cancer. The exogenous wild type p53 could in-
crease chemo sensitivity in three anaplastic thyroid carcin-
oma cell lines (BHT-101, SW-1736, and KAT-4), which
had nonfunctional p53 and ATC cell lines have been
observed [21]. It is probable that the majority of thyroid
cancers activate an alternative pathway that compromises
the function of wild-type p53. Well-differentiated thyroid
cancers generally do not express a mutation in p53 [22].
Clinical trials were carried out using recombinant
adenoviral-encoded human p53 gene (rAd-p53), com-
bined with intensity-modulated radiation therapy (IMRT)
for treatment of 46 patients with historically-diagnosed
stage IV PTC. The patients received intratumoral injec-
tion. A month later, 76% (19/25) of patients underwent
radical surgery. One-year survival rate was 96% and no
local recurrence and distant metastases were observed in
the cohort of patients with surgery [23]. Currently, the
clinical trials, rAd-p53 gene therapy for advanced malig-
nant thyroid tumors (stage III/IV) is in phase IV [24].
When ONYX-015 was combined with the standard che-
motherapeutic agents cisplatin and 5′-fluorouracil to com-
bat TMN, a considerable efficacy was reported in a
proportion of cases [25]. ONYX-015 proved safe at a dose
up to 2 × 1012 viral particles [26]. So far, ONYX-015 is the
only oncolytic virus product on the market [27]. E1A-
defective adenovirus dl922-947 and DeltaE1B55K (dl1520)
mutants were compared in human thyroid anaplastic car-
cinoma cells in vivo and in vitro. The efficacy of dl922-947
exceeded that of dl1520 in all tested anaplastic thyroid car-
cinoma cells. The combination of dl922-947 with bevaci-
zumab reduced significantly tumor growth compared with
single treatments alone [28]. Recently, an important genet-
ically modified antiangiogenic adenovirus, termed VB-111,
exhibited to have significant antitumor activity for thyroid
cancer. VB-111 expresses Fas-c in angiogenic blood ves-
sels. VB-111 treatment resulted in 26.6% (P =0.0596),
34.4% (P =0.0046), and 37.6% (P =0.0249) inhibition of
tumor growth in follicular, papillary and anaplastic thyroid
cancer cell line models, respectively. No toxicity was
observed in these studies [29]. The clinical trial based on
VB-111 for oncolysis is currently underway for patients
bearing thyroid malignant neoplasm. The multi-dose
VB-111 phase II clinical trial dealt with the treatment of
patients with gliobastoma multiforme, differentiated
thyroid cancer and ovarian cancer (NCT0120506).
Reovirus - preclinical and clinical studies
Mammalian orthoreoviruses (reoviruses) are ubiquitous
viruses that infect cells in the respiratory and enterictracts. Reoviruses have a 70-85 nm diameter and are non-
enveloped nearly spherical icosahedral particles. The icosa-
hedral capsid is composed of an outer and inner protein
shell. The double stranded RNA (dsRNA) genomes contain
10–12 segments, which are grouped into three categories
corresponding to their size: L (large), M (medium) and S
(small). Segments range from approximately 1 Kb to 3.9
Kb and each segment encodes 1–3 proteins (the L segment
encodes for λ proteins, the M segment encodes for μ
proteins and the S segment encodes for σ proteins).
Replication occurs in cytoplasm and viral particles
begin to assemble in the cytoplasm 6–7 hours after
infection [30]. The virus can enter the host cell via an
unknown cell surface receptor. The receptor is thought
to include sialic acid and junctional adhesion mole-
cules (JAMs). Reovirus is not considered a human
pathogen, due to the absence of obvious symptoms, or
known clinical impact during natural or experimental
infection [31]. The virus seropositivity approaches 100% in
adults [32].
The reoviruses have oncolytic properties, which are
a bonus for the development of reovirus-based therap-
ies for cancer treatment. Ikeda et al. proved that reo-
virus was effective to inhibit the growth of human head
and neck squamous cells in vitro and in vivo [33].
Moreover, the efficacy of reovirus can be enhanced by
combination with chemotherapy. A triple reovirus, cis-
platin and paclitaxel combination showed a signifi-
cantly more effective targeting than reovirus combined
with either cisplatin, or paclitaxel [34]. These studies
were carried out in four head and neck cancer cell lines
in vitro and in vivo. The in vivo studies consisted of
subcutanoeus injection of four head and neck cancer
cell lines in athymic nude mice [34]. A Phase II clinical
trial investigated the antitumor effects of intratumoral
administration of REOLYSIN® in combination with
low-dose radiation in patients with advanced cancers.
A total of sixteen patients with advanced cancer were
enrolled in the trial. Of these, partial responses were
observed in two patients (thyroid, ovarian), for a total
disease control rate of 93% in the treated lesions [35].
RT3D was combined with carboplatin/paclitaxel in
patients with advanced cancers. Thirty-one heavily
pretreated patients received study therapy in the phase
I/II studies [36]. In summary, of the current phase I/II
studies, reovirus showed safety both as a single agent
when administered intratumorally and intravenously,
as well as in combination therapy, with multiple che-
motherapeutics such as gemcitabine, carboplatin and/
or paclitaxel, and docetaxel. Similar findings were
observed with radiation. Reovirus was therapeutically
formulated and used in a phase III registration study in
metastatic squamous cell carcinoma of the head and
neck [37,38].
Guan et al. Journal of Experimental & Clinical Cancer Research 2014, 33:91 Page 4 of 11
http://www.jeccr.com/content/33/1/91Herpes Simplex Virus – 1 - preclinical and clinical studies
The Herpes Simplex Virus – 1 (HSV-1) virion ranges
from 180 to 300 nm in diameter and comprise an
outer-lipid bilayer envelope embedded with glycopro-
teins. Beneath the envelope lies the tegument layer,
which contains proteins and enzymes important in
early virus infection. The capsid contains the large
dsDNA genome, consisting of 152,261 base pairs in length
and with a base composition of 67% G + C. HSV-1 has
approximately 90 open reading frames, allowing for the
transcription of at least 84 unique proteins [39]. HSV
enters into the cell by fusion of the viral envelope
proteins. Virus initial interactions occur when a viral
envelope glycoprotein C binds to a cell surface particle
called heparan sulfate. A second glycoprotein, glycopro-
tein D, binds specifically to at least one of three known
entry receptors [40]. These include HSV entry mediator,
nectin-1 and 3-O sulfated heparan sulfate. Once bound
to the mediator, gD interacts with viral glycoproteins H
and L complex. In cells that are permissive for the
propagation of this virus, the replication cycle is usually
completed within 20 hours, releasing viral progeny
through cell lysis. HSV-1 infection is extremely com-
mon and approximately 90% of adults have been ex-
posed to the virus. The virus can be spread through
contact with saliva. Symptoms of herpes simplex virus
infection include watery blisters in the skin, or mucous
membranes of the mouth, lips or genitals. As neuro-
tropic and neuroinvasive viruses, HSV-1 persists in the
body by becoming latent in the cell bodies of neurons.
Some infected people may experience sporadic episodes
of viral reactivation [41].
The strategies used in adenovirus work were also uti-
lized in designing oncolytic HSV, such as expression of
the tk in the tumor, followed by GCV administration, or
other chemotherapeutic drugs, which are converted by
tk into a cell-lethal metabolite in human thyroid carcin-
oma cell lines and in nude mice [42]. Soler et al. [43]
evaluated a strategy for treatment of MTC, combining
“suicide” and IL-2 gene therapies. Tumors were pro-
duced in Wag/Rij rats by orthotopic injection of the
rMTC 6–23 cell line, and/or derivatives expressing the
HSV1-TK gene (rMTC-TK). GCV, which is selectively
transformed into a toxic metabolite by HSV1-TK, totally
eradicated rMTC-TK tumors in 60% of the animals [43].
In a similar study, the expression of both the HSV-TK
and the hIL-2 therapeutic genes in infected cells was
high and persistent with time and showed that treatment
with GCV led to more than 90% tumor growth inhib-
ition and 100% inhibition transduced cells proliferation
[44]. Moreover, successful safety and efficacy preclinical
studies were conducted in NV 1023 and G207 cell lines,
both in vitro and in animal models. Yu et al. [45] tested
the oncolytic HSV (NV1023) against seven differentthyroid cancers, including one papillary (NPA-187), one
follicular (WRO82-1), one medullary (DRO81-1) and four
anaplastic (DRO90-1, ARO, KAT-4C and KAT-18) cell
lines. With the exception of WRO82-1 cell line, all other
cell lines at MOI 5 demonstrated >95% infection in vitro
at day 2. DRO81-1 tumors demonstrated partial response
and all NPA-187 tumors in athymic nude mice completely
regressed following the administration of a single dose
[45]. A preclincial study utilized HSV NV 1023 strain,
which expresses HSV glycoprotein D receptors nectin-1
and HSV entry mediator [46]. The HSV NV 1023 strain
exhibited cytotoxicity greater than 85% in anaplastic, me-
dullary and papillary cancers [46]. Another study used
HSV G207 and NV1023 strains in combination with pacli-
taxel and doxorubicin to induce oncolysis in three human
anaplastic thyroid cancer cell lines [47]. A dose-dependent
cytotoxicity was observed for all four agents. Interestingly,
G207 exhibited synergistic cytotoxicity, when combined
with paclitaxel. A single intra-tumor injection (it) of G207
combined with biweekly intraperitoneal (ip) injection of
paclitaxel injections in athymic nude mice bearing human
anaplastic KAT4 cell line in a flank showed significantly
reduced mean tumor volume [47].
The following clinical trials were not designed for the
TMN treatment; however they may provide useful infor-
mation about the employment of HSV as vector for
virotherapy. SEPREHVIR (HSV-1716) was utilized in
three clinical trials to treat 47 patients with glioma, 5 pa-
tients with melanoma and 20 patients with squamous
cell carcinoma of the head and neck [48,49]. No toxicity
attributable to the use of HSV1716 was reported in any
of these clinical studies. A new phase I/IIa clinical study for
the treatment of mesothelioma commenced in 2012 [48].
This trial is based on HSV-1 and was previously tested in a
Phase I trial for other solid tumors, such as melanoma, liver
cancer, pancreatic cancer, lung cancer (NCT01935453) and
head and neck cancer (NCT00931931). Efficacy and Safety
Study of OncoVEXGM-CSF compared to GM-CSF in
patients with melanoma is ongoing (NCT00769704) [49].
Vaccinia Virus - preclinical and clinical studies
Vaccinia virus (VV) is a member of the genus Orthopox-
virus of the family of Poxviridae. VV is a large dsDNA
virus whose entire life cycle takes place within the cyto-
plasm of host cells. Vaccinia intercellular mature virus
(IMV) particles are brick-shaped, approximately 300 ×
240 × 120 nm in size, with a lipoprotein shell surrounding
a complex core structure [50]. The core structure contains
a linear, ds DNA genome of approximately 192 kb associ-
ated with a number of virus-encoded proteins [51]. VV
has inverted terminal repeats (ITRs) that are required for
VV DNA replication. The 192-kb genome encodes some
200 genes that are largely non-overlapping. VV produces
three forms of infectious particles: IMV, cell-associated
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(EEV) with a different cell surface binding sites [50]. IMVs
enter cells by fusion with the plasma membrane [52]. EEVs
enter cells by endocytosis followed by low pH disruption
of the EEV outer membrane and fusion of the released
IMV with endosomal membranes [53]. It typically begins
1–2 h after infection and generates large numbers of gen-
ome copies per cell within hours of infection, of which half
are ultimately packaged into infectious virions [54]. The
host response to VV infection is multifactorial. Immedi-
ately after VV invasion, nonspecific mechanisms involving
apoptosis induction, complement, interferons, cytokines
and natural killer cells serve as the first-line host defense.
[55]. Although neutralizing antibodies are also involved in
host protection during VV infection, the cell-mediated
immune responses are known to be particularly potent
and may be most critical for viral clearance [56]. T helper
1 (Th1) immune response is mediated by antiviral cyto-
kines such as IL-12, IL-18 and interferon (IFN)-γ, and
plays a critical role in host defense [57,58]. Th2 immune
response is mediated by IL-4 and IL-10 and may actually
suppress the host response to vaccinia [59]. In addition,
due to VV infection, the host cell shut-off is the abroga-
tion of class I and class II major histocompatibility com-
plex (MHC) molecule production and presentation,
thereby leading to poor recognition of the virus by T cells
[60]. At least two virus-encoded factors were shown to
inhibit the complement cascade: C3L and B5R. VV
encodes at least three proteins to inhibit premature
cell death caused by apoptosis [61].
The majority of studies for TMN in oncolytic mutant
vaccinia virus were designed to assess the viral oncolysis
efficacy in thyroid cell lines and animal models of
thyroid malignant tumors [62]. For example, vaccinia
virus strain recombinant GLV-1 h68 infection was
detected in all cell lines in 24 hours and increased in in-
tensity at 36 hours in six ATC cell lines after inoculation
[63,64]. In vivo studies showed an enhanced anti-tumor
efficacy with one i.v. GLV-1 h68 injection followed by
multiple i.p. injections of Avastin [65]. Expression of
human NIS (hNIS) was also used in the VV work
[66,67]. Vaccinia virus (GLV-1 h153) carrying hNIS was
able to infect, replicate and kill all ATC cell lines. At a
MOI of 1.0, GLV-1 h153 reached near 100% cytotoxicity
in 8305c and FRO at day 5. The efficacy of the treat-
ment was also observed in infected ATC xenografts
[66,67]. In addition, GLV-1 h153 achieved more than
90% cytotoxicity in human gastric cancer cell lines and
xenografts [68].
Currently, there are no virotherapy clinical trials based
on VV for the treatment of TMN. However, the VV results
obtained from several other trials are certainly interesting.
The phase I clinical trial that utlized GL-ONC1 proved
that the virus could safely be administered intravenouslyin patients with advanced solid tumors [69]. JX-594
(Pexa-Vec) is a VV engineered by addition of the GM-CSF
gene and deletion of the thymidine kinase gene, which
limits viral replication to cells with high levels of thymidine
kinase, typically seen in cancer cells with a mutated
RAS or p53 gene [70]. It has orphan drug designation
from US FDA and EUMA for the treatment of hepato-
cellular carcinoma (HCC). Two phase I trials were con-
cluded and a phase II trial for primary liver cancer,
alone and in combination with sorafenib is starting.
Both GL-ONC1 and JX-594 provided promising results
in preclinical studies [71].
Newcastle disease virus - preclinical and clinical studies
Newcastle disease virus (NDV), also known as avian
paramyxovirus-1 (APMV-1) and belongs to the genus
Avulavirus of the family Paramyxoviridae. NDV is envel-
oped and spherical, with a diameter in the range of
150 nm and the genome consists of single stranded
negative-sense RNA (ssRNA) that contains six open
reading frames (ORF) and comprises 15,186 nucleo-
tides. The six ORF encode the nucleoprotein (NP), the
phosphoprotein (P), the matrix protein (M), the fusion
protein (F), the haemagglutinin-neuraminidase (HN)
and the large protein (L). At least one additional non-
structural protein (V) and possibly a second one (W)
are generated by RNA editing during P gene transcrip-
tion [72]. Virus infection is initiated by attachment of
the virion to the surface of the target cell. Binding of the
viral HN glycoprotein to sialic acid-containing cell
surface proteins, which serve as receptors, triggers the
F protein promoted fusion of the viral envelope with
the plasma membrane of the host cell through a pH-
independent mechanism [73]. NDV has only one serotype
and causes Newcastle disease, which is a contagious bird
disease. The virus is transmissible to humans and can
cause mild conjunctivitis and influenza-like symptoms
[74]. NDV replicate up to 10,000 times faster in human
cancer cells than in most normal human cells. NDV is a
naturally oncolytic virus that has been shown to be safe
and effective for cancer therapy. In 1999, promising results
were reported using an attenuated strain of the NDV [75].
Recombinant NDV is an effective oncolytic agent against
a panel of tumor cell lines including thyroid, head and
neck, and mouse model [76]. For example, NDV (F3aa)-
GFP, a genetically modified fusogenic NDV, was used for
the treatment of head and neck squamous cell carcinoma.
Four cell lines were highly susceptible to viral cytotoxicity,
with more than 75% of cells lysed at day 6 at MOI 0.1,
whereas two other cell lines were partially susceptible.
Oncolytic NDV was used in a number of in vivo studies
for the effective target of various solid tumors [77,78].
So far, no clinical investigation has been initiated with
NDV for TMN. However, four clinical trials have been
Guan et al. Journal of Experimental & Clinical Cancer Research 2014, 33:91 Page 6 of 11
http://www.jeccr.com/content/33/1/91conducted in the United States studied the use of NDV
oncolysates in patients with metastatic melanoma. Some
positive results were found in these studies [79].
Vesicular stomatitis virus - preclinical and clinical studies
The vesicular stomatitis virus (VSV) is a single negative
ssRNA virus. VSV is a member of the Rhabdoviridae
family, which includes the rabies virus. The virus particle
carries a single approximately 11-kb (−) RNA encoding
five genes: the nucleocapsid protein N, the phosphor-
protein P, the matrix protein M, glyco protein G and the
large polymerase protein L. The G spikes on the outside
of the virus particles will help to attach to other cells that
can be infected. The VSV G protein mediates viral attach-
ment either to Low-Density Lipoprotein (LDL) receptor
(LDLR), or an LDLR family member present on the host
cell. Following binding, the VSV-LDLR complex is rapidly
endocytosed. It then mediates fusion of the viral envelope
with the endosomal membrane [80]. The M protein is part
of the inner membrane of the virus and is responsible for
shutting down the host and the viral translation. VV repli-
cation occurs in the cytoplasm [81]. There are two distinct
immunological classes of VSV recognized: New Jersey
(NJ) and Indiana (IND). In humans, the incubation period
may vary from 24 hours to 6 days but it is usually 3–4
days. VSV grows rapidly, is zoonotic and non-pathogenic
to humans [82]. VSV only causes a flu-like illness in in-
fected humans [82].
The efficiency of VSV to express either human or
murine IFN-β, or a methionine deletion at residue 51 of
the matrix protein was been observed in vitro and
in vivo [83]. Currently, there is no clinical investigation
that utilizes VSV for the treatment of TMN. A VSV-
based phase I trial is currently underway for the treat-
ment of patients with liver cancer (NCT01628640). In
this clinical, VSV particles expressing human interferon
beta will be administered into patients via intratumoral
injection.
Measles Virus - preclinical and clinical studies
Measles virus (MV) is a single-stranded, negative-sense,
enveloped RNA virus of the genus Morbillivirus of the
family Paramyxoviridae. The measles virus has two enve-
lope glycoproteins on the viral surface: hemagglutinin
(H) and membrane fusion protein (F). These proteins
are responsible for host cell binding and invasion. Three
receptors for the H protein have been so far identified:
complement regulatory molecule CD46, the signaling
lymphocyte activation molecule (SLAM) and the cell
adhesion molecule Nectin-4 [84]. Humans are the nat-
ural hosts of the virus. No animal reservoirs are known
to exist. This virus is the cause of measles, an infection
of the respiratory system. Approximately 500,000 per-
sons with measles are reported each year in the UnitedStates [85]. The vaccine-attenuated strains of MV show
a promising potential for cancer therapy [86]. There is
a study that utilizes MV-Edm, which was modified to
include the NIS gene to be combined with radiology
treatment. This study demonstrated the oncolytic effi-
cacy of MV-NIS in BHT-101 and KTC-3, ATC-derived
cell lines and mouse model [87].
There is no MV clinical investigation for TMN yet.
However, there are two phase I trials that are recruiting
patients with other types of malignancies. One trial will
studying the side effects and best dose of the MV de-
rivative producing CEA (MV-CEA) to treat patients with
recurrent glioblastoma multiforme (NCT00390299). An-
other MV-NIS phase I trial will study the side effects and
the best dose of viral therapy to treat patients with recur-
rent or metastatic squamous cell carcinoma of the head
and neck (NCT01846091).
Retrovirus - preclinical and clinical studies
The murine leukemia virus (MLV) is one of the simplest
retroviruses. The virus has a spherical shape that has a
diameter of 80 to 100 nm. The envelope of the virus is
covered with glycoprotein spikes. The viral genome is a
single stranded, linear, positive-sense RNA molecule of
approximately 8,000 nucleotides and 4 ORF. The gen-
ome contains gag, pol, and env regions, which encode
for structural proteins, enzymes including the RNA-
dependent DNA polymerase (reverse transcriptase), and
coat proteins, respectively [88].
A MLV-derived retroviral vector termed pMFGIL-
2TKSN expresses two therapeutic genes, such as HSVtk
and IL-2. This retroviral-based vector system exhibited
enhanced tumor growth inhibition in animal models
[89]. In addition, Barzon et al. [44] used a similar retro-
viral vector system and evaluated its efficiency in vitro
and in vivo, following GCV treatment [90]. This study
showed an 80% reduction of the size of differentiated
thyroid carcinomas [44]. Two patients with end-stage
anaplastic thyroid carcinoma were treated with direct
intratumor injection of retroviral vector expressing the
human IL-2 gene and the suicide gene tk of HSV 1,
followed by GCV administration. The treatment was safe
and demonstrated local tumor necrosis [91]. To date,
the RV clinical investigation has not been reported for
TMN. A phase I study will test the safety of different
doses of the patients own immune cells, which will be
genetically modified to help recognize and destroy the
cancer cells for treatment of castrate metastatic prostate
cancer (NCT01140373).
Consideration for the oncolytic virus design
Based on previous research, oncolytic virus replication
in normal cells remains a concern and, therefore, the
efforts should be focused on improving the oncolytic
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city of oncolytic virus is a most important factor that
would eventually determine the clinical safety and effi-
cacy for the therapeutics. Specific targeting of tumour
cell can be achieved by taking advantage of the fact that
tumour cells have altered microenvironment, display
certain tumour specific receptors and modified cellular
pathways [93]. In fact, the specificity of oncolytic virus
depends on the oncolytic virus tropism, which can be
modified. For example, expression profiles of multiple
microRNAs can reshape the tropism of MV, which could
be safer and efficient for a high-dose systemic adminis-
tration [94]. Indeed, viruses with altered tropism may be
used for the targeting of tumor-specific surface bio-
markers. Several TMN immuno-histochemical and mo-
lecular biomarkers have been proposed. Some of them
might be useful for this purpose, or for diagnosis. Bio-
markers for TMN comprise: RET, vascular endothelial
growth factor receptor, hepatocyte growth factor re-
ceptor, epidermal growth factor receptor, ATP-binding
cassette sub-family G member 2, cytokeratin 19 (CK19),
galectin-3, oncofetal fibronectin (OnfFN), hector battifora
mesothelial cell 1, CD44, CD56, CD63, CD113, CD133,
lysosomal enzymes cathepsin B, cathepsin L and lysosomal
dipeptidyl peptidase II [95-97]. The distribution of these
biomarkers in TMN is variable. Demellawy et al. [98]
reported that the CD56 positive in all the lesions and
tumors except for PTC in all cases (100%). CD56 was
negative in all PTC cases (100%). CK19 showed positive
expression in PTC accounting for 85% of cases and inFigure 1 TSHR localization and structure. (A) Thyroid follicle, where the
uptake and organification into thyroglobulin. (B) TSHR protein structure, show
and the β subunit composed of 7 trans-membrane domains, the intra-cel
permission from Atlas Genet Cytogenet Oncol Haematol [103].26% of non-PTC lesions/tumors. P63 expression was in
70% of cases of PTC and was consistently absent in all
the non-PTC cases [98]. Medullary thyroid carcinomas
account for less than 5% of thyroid nodules and exhibit
a specific circulating biomarker, i.e. calcitonin (CT). An-
other major issue is the relevance of oncogene mutation
and signaling transduction in TMN. The genetic alter-
ation described in PTC is the RET/PTC rearrangement,
encoding for a transmembrane tyrosine kinase receptor.
The incidence of RAS mutations in these different his-
totypes ranges from 0%–50% in PTC, 14%–62% in FTC
and 0%–60% in ATC. The over-expression of the MET/
HGF receptor is 100-fold higher in PTC than in FTC,
ATC and MTC [99]. In conclusion, a panel of biomarkers
was studied for TMN. However, there is no validated bio-
marker that is specific for TMN.
It has been previously reported that BRAF mutations
and rearrangements of RET (RET/PTC) prevent the
differentiation of thyroblasts into prothyrocytes, result-
ing in the generation of papillary carcinomas, whereas
PAX8-PPARγ1 rearrangement prevents differentiation
of prothyrocytes into thyrocytes, resulting in the gener-
ation of follicular tumors [100]. We understand that
human thyroid ancestor cells or embryonic stem cells
(ES) cell-derived, endoderm-positive cells have been shown
to express several early thyroid markers. For example, ana-
plastic carcinoma (Tg -, OnfFN +) derives from thyroid
stem cells, papillary carcinoma (Tg+, onfFN +) from
thyroblast cells, and follicular tumor (Tg+, onfFN -)
from prothyrocytes, respectively [101]. According toTSH-stimulated synthesis of thyroid hormone occurs following iodide
ing the β subunit composed of leucine-rich repeats and the N-terminus,
lular and extra-cellular loops and the C-terminus. Figure adapted with
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different mutations during thyroid fetal development.
Thus, any event that prevents fetal thyroid cells from
differentiation might stop carcinogenesis. Some thyroid
specific biomarkers were expressed during normal human
fetal development. Between E60 and E70, a series of events
lead the thyroid primordial toward a functional thyroid
gland able to produce and release hormones during the
normal thyroid development in embryology [102]. The
thyroid markers appear in that period. These include
thyroglobulin (Tg), NIS, thyroid peroxidase (TPO),
thyroid-stimulating hormone (TSH), and TSH receptor
(TSHR) [102] (Figure 1) [103]. This information sug-
gests that the thyroid markers, such as TSH, may be
more useful for TMN virotherapy. TSH is a glycoprotein
and consists of two subunits, the alpha (α) and the beta
(β) subunit. The α subunit, a 92-amino acid sequence,
is thought to be the effector region responsible for
stimulation of adenylate cyclase (involved the gener-
ation of cAMP). The β subunit (TSHB), a 118-amino
acid sequence, is unique to TSH, and therefore deter-
mines its receptor specificity [104,105]. The TSHR is
mainly found on thyroid follicular cells. TSH binds
TSHR with high affinity. TSHR is widely expressed in a
variety of extrathyroidal tissues [102]. The level and the
tissues distribution of TSHR and TPO are very similar
to the distribution of NIS. Therefore, TSHR (or TPO)
might still be considered as a fetal thyroid marker,
which can be used for oncolytic virotherapy. Another
strategy consists of expressing the Fab fragment of anti-
bodies anti-TSHR, or anti-TPO, or anti-NIS. This might
increase the oncolytic virus binding and/or entry specific-
ally for cells expressing TSHR, or TPO, or NIS.
In addition, previous studies that utilized VSV and NDV
as oncolytic agents provided encouraging results. More-
over, VSV and NDV are zoonotic pathogens. Humans have
little to no immunity against these viruses, which facili-
tates their escape from host immune system. This allows
for the oncolytic viruses to reach and kill malignant cells.
Virtually, the final step to success is the selection of the
site and route for virus delivery. Current studies have
emphasized intratumoral delivery. The direct tumor injec-
tion cannot kill the tumor cells in blood stream, which
may cause the tumor recurrence. Therefore, the systemic
delivery through the bloodstream to reach cancer cells will
be necessary. Studies are ongoing to improve efficient
delivery of oncolytic viruses into the host. To this end,
preclinical studies are focusing on the use of cellular
carriers of oncolytic viruses [106]. The cellular carriers
may shield oncolytic virus from neutralizing antibodies
during delivery, providing a simple and effective tool to
enhance the therapeutic efficacy of oncolytic viruses
[106]. However, as a human therapeutic agent, the max-
imum purity that related with agent’s safety and efficacyis very important. An improper agent preparation might
cause some unacceptable adverse events. Therefore, it is
important to improve the safety of therapeutic bio-
logical agents used in therapy. In this respect, the tech-
niques used in the pharmaceutical industry to optimize
the formulation and lyophilization of live viral vaccines
might be applied to oncolytic virus preparations.
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